Investors Wake Up To Success Of Idorsia Sleep Drug
Positive Phase III Data For Daridorexant
Executive Summary
The Swiss biotech says that a late-stage trial of the dual orexin receptor antagonist daridorexant is the first study to demonstrate an insomnia product that can improve how the patient feels during the day, as well as aiding sleep at night.
You may also be interested in...
Finance Watch: Investors Bet Billions On Big Biopharma Offerings
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
UK Biotechs Still Set On Cashing Out
Excluding the multinational majors AstraZeneca and GSK, the UK has yet to produce a truly successful scaled pharma company, despite having boasted several innovative start-ups. Whether that represents a negative, however, is a matter for debate.
Asarina And Emalex Carry The Torch For Tourette's
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.